HIV Vaccine Development:

Pan-African Considerations


Supporting development of a pan-African HIV vaccine agenda and facilitating strategic planning to ensure development of vaccine strategies for all populations in need

With only 5 percent of the world’s population, Eastern and Southern Africa is home to half the world’s population living with HIV. Today the African continent continues to be the epicenter of the HIV/AIDS epidemic, with 48% of the world’s new HIV infections among adults and 55% among children.

Multiple HIV-1 subtypes are prevalent on the African continent: subtypes A and D are stable in East Africa; C in southern Africa; A, G, CRF02_AG and CRF06-cpx in western Africa; and subtype B and CRF02-A in northern Africa. This diversity in HIV-1 subtypes as well as infection with multiple viral variants and recombinant viruses has presented a challenge for vaccine development.

Various groups are advancing different vaccine strategies, including subtype neutral designs for global use, hoped to be successful against most or all subtypes of HIV. This diversity of strategies provides an opportunity to review and discuss the vaccine pipeline, burden of disease in the different African regions, existing African cohorts with high enough incidence for future efficacy trials, and ways forward to determine how broad or narrow protection, if observed, will be. The meeting will discuss the optimal design of initial efficacy trials and potentially bridging studies to ensure the broadest possible benefit of candidates in regions that didn’t participate in a successful efficacy trial, since widespread use will need to be expedited when deployable results are obtained.

Objectives and deliverables

  • Review the existing pipeline of vaccine approaches (vectors/platforms and inserts) and discuss how they can be evaluated to facilitate access for all populations in Africa (and, by extension, world-wide).
  • Review existing African cohorts with high enough incidence, and viral and human genetic diversity for the most informative analyses.
  • Discuss the latest data on breadth of immune responses and how this may affect the need for additional studies to ensure vaccine efficacy in all subtypes and host genetics.
  • A report with recommendations will be produced and distributed to Enterprise stakeholders and made available for African decision makers.

Date and location

A two-day meeting held in Kigali, Rwanda, 16-17 March 2015.


  • Prince Bahati, International AIDS Vaccine Initiative, Kenya
  • Gavin Churchyard, Aurum Institute, South Africa
  • Vinodh Edward, Aurum Institute, South Africa
  • Pat Fast, International AIDS Vaccine Initiative, US
  • Glenda Gray, South African Medical Research Council, South Africa
  • Ilesh Jani, Instituto Nacional da Saúde, Mozambique
  • Pontiano Kaleebu, MRC/UVRI Uganda Research Unit on AIDS, Uganda
  • Etienne Karita, Projet San Fransisco, Rwanda
  • Hannah Kibuuka, Makerere University, Walter Reed Project, Uganda
  • William Kilembe, Rwanda Zambia HIV Research Group, Zambia
  • Amapola Manrique, Global HIV Vaccine Enterprise, US
  • Gaudensia Mutua, University of Nairobi KAVI-ICR, Kenya
  • Merlin Robb, US Military HIV Research Program, US
  • Fred Sawe, Kenya Medical Research Institute/Walter Reed Project, Kenya
  • Bill Snow, Global HIV Vaccine Enterprise, US
  • Tim Tucker, SEAD, South Africa
  • Anna-Lise Williamson, University of Cape Town, South Africa
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account